- Molecular NameGliclazide
- Synonym1-(3-Azabicyclo(3; 3; 0)oct-3-yl)-3-(p-tolylsulfonyl)urea; 1-(Hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea; Gliclazida [INN-Spanish]; Gliclazidum [INN-Latin]; N-(4-Methylbenzenesulfonyl)-N'-(3-azabicyclo(3; 3; 0)oct-3-yl)urea
- Weight323.417
- Drugbank_IDDB01120
- ACS_NO21187-98-4
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)2.09
- pka5.98
- LogD (pH=7, predicted)0.95
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.96
- LogSw (predicted, AB/LogsW2.0)0.39
- Sw (mg/ml) (predicted, ACD/Labs)0.18
- No.of HBond Donors2
- No.of HBond Acceptors6
- No.of Rotatable Bonds3
- TPSA86.89
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn oral hypoglycemic (anti-diabetic drug) and is classified as a sulfonylurea.
- Absorption_value97.0
- Absorption (description)Absorbed after oral administration.
- Caco_2N/A
- Bioavailability97.0
- Protein binding90.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt is extensively metabolised by hydroxylation, N-oxidation and oxidation to several inactive metabolites; the p-carboxy metabolite, which accounts for about 1% of the plasma concentration, has no hypoglycaemic activity but has some antithrombotic activity.
- Half life10 h
- ExcretionAbout 60 to 70% of a dose is excreted in the urine with less than 5% as unchanged drug. The p-carboxy and N-oxide metabolites account for about 40% of the dose. About 10 to 20% of the dose is eliminated in the faeces as metabolites.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)LD50=3000 mg/kg